X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (28547) 28547
Newspaper Article (57) 57
Book Chapter (30) 30
Newsletter (19) 19
Magazine Article (15) 15
Dissertation (9) 9
Publication (7) 7
Book / eBook (5) 5
Book Review (1) 1
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (23969) 23969
science & technology (23233) 23233
life sciences & biomedicine (21599) 21599
female (16632) 16632
male (15903) 15903
oncology (14733) 14733
middle aged (14347) 14347
aged (13502) 13502
lung neoplasms - mortality (10341) 10341
carcinoma, non-small-cell lung - mortality (9607) 9607
lung neoplasms - pathology (9453) 9453
prognosis (9274) 9274
adult (9022) 9022
lung cancer (8685) 8685
carcinoma, non-small-cell lung - pathology (7998) 7998
cancer (7317) 7317
neoplasm staging (7017) 7017
aged, 80 and over (6035) 6035
lung cancer, non-small cell (6016) 6016
lung neoplasms - drug therapy (5673) 5673
carcinoma, non-small-cell lung - drug therapy (5479) 5479
metastasis (4857) 4857
chemotherapy (4851) 4851
survival rate (4811) 4811
treatment outcome (4789) 4789
tumors (4450) 4450
retrospective studies (4428) 4428
care and treatment (4417) 4417
surgery (4280) 4280
survival analysis (4173) 4173
lung neoplasms - surgery (3995) 3995
analysis (3970) 3970
medical prognosis (3862) 3862
research (3832) 3832
respiratory system (3790) 3790
carcinoma, non-small-cell lung - surgery (3759) 3759
lung neoplasms - genetics (3521) 3521
non-small cell lung cancer (3493) 3493
gene expression (3416) 3416
carcinoma, non-small-cell lung - genetics (3300) 3300
cancer therapies (3281) 3281
patients (3093) 3093
antineoplastic combined chemotherapy protocols - therapeutic use (2987) 2987
immunohistochemistry (2913) 2913
cell line, tumor (2910) 2910
apoptosis (2890) 2890
disease-free survival (2879) 2879
health aspects (2839) 2839
proteins (2808) 2808
kaplan-meier estimate (2787) 2787
non-small cell lung carcinoma (2769) 2769
genetic aspects (2642) 2642
follow-up studies (2586) 2586
survival (2514) 2514
squamous cell carcinoma (2460) 2460
development and progression (2455) 2455
risk factors (2453) 2453
studies (2253) 2253
lung neoplasms - therapy (2252) 2252
animals (2225) 2225
mutation (2210) 2210
lung neoplasms - metabolism (2209) 2209
gene expression regulation, neoplastic (2207) 2207
medicine & public health (2154) 2154
kinases (2138) 2138
metastases (2120) 2120
carcinoma, non-small-cell lung - therapy (2078) 2078
antineoplastic agents - therapeutic use (2074) 2074
research article (2064) 2064
hematology, oncology and palliative medicine (2028) 2028
carcinoma, squamous cell - pathology (2022) 2022
medicine (1993) 1993
biomarkers (1987) 1987
carcinoma, squamous cell - mortality (1976) 1976
cell proliferation (1961) 1961
proportional hazards models (1931) 1931
carcinoma, non-small-cell lung - metabolism (1923) 1923
cell biology (1908) 1908
pathology (1839) 1839
mortality (1815) 1815
multivariate analysis (1790) 1790
lung cancer, small cell (1687) 1687
combined modality therapy (1645) 1645
science & technology - other topics (1642) 1642
radiotherapy (1626) 1626
lung neoplasms - diagnosis (1613) 1613
multidisciplinary sciences (1608) 1608
lung neoplasms - radiotherapy (1597) 1597
patient outcomes (1596) 1596
time factors (1586) 1586
medical research (1560) 1560
cell growth (1559) 1559
adenocarcinoma - mortality (1543) 1543
carcinoma, non-small-cell lung - radiotherapy (1536) 1536
cell cycle (1529) 1529
liver cancer (1521) 1521
hepatocellular carcinoma (1508) 1508
lymphatic metastasis (1494) 1494
nsclc (1456) 1456
mice (1453) 1453
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (27931) 27931
Japanese (247) 247
Chinese (246) 246
German (208) 208
French (195) 195
Spanish (70) 70
Russian (41) 41
Portuguese (35) 35
Polish (32) 32
Italian (30) 30
Czech (16) 16
Turkish (15) 15
Norwegian (10) 10
Bulgarian (8) 8
Dutch (8) 8
Hungarian (8) 8
Danish (7) 7
Icelandic (6) 6
Korean (6) 6
Serbian (6) 6
Lithuanian (4) 4
Romanian (4) 4
Croatian (3) 3
Swedish (3) 3
Finnish (2) 2
Hebrew (2) 2
Arabic (1) 1
Bosnian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 08/2017, Volume 377, Issue 9, pp. 829 - 838
...–small-cell lung cancer. Importantly, it reduced the risk of CNS relapse. 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 03/2014, Volume 370, Issue 13, pp. 1189 - 1197
...–small-cell lung cancer (NSCLC), ALK rearrangement occurs in approximately 5% of cases. 2 – 8 ALK -rearranged tumors depend on ALK for growth and survival and show marked sensitivity to ALK inhibitors such as crizotinib... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors
Journal Article
The New England journal of medicine, ISSN 1533-4406, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had similar response rates, but osimertinib... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 22, pp. 2078 - 2092
The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival than chemotherapy alone... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Carcinoma, Non-Small-Cell Lung - secondary | Aged, 80 and over | Adult | Female | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Treatment outcome | Care and treatment | Chemotherapy | Usage | Analysis | Lung cancer, Non-small cell | Drug therapy | Cancer | Epidermal growth factor receptors | Laboratories | Lung cancer | Non-small cell lung carcinoma | Cytotoxicity | Metastasis | Patients | Cancer therapies | Metastases | Pembrolizumab | Hospitals | Platinum | PD-L1 protein | Response rates | Death | Mutation | Apoptosis
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 379, Issue 21, pp. 2040 - 2051
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Journal Article
by Jamal-Hanjani, Mariam and Wilson, Gareth A and McGranahan, Nicholas and Birkbak, Nicolai J and Watkins, Thomas B.K and Veeriah, Selvaraju and Shafi, Seema and Johnson, Diana H and Mitter, Richard and Rosenthal, Rachel and Salm, Max and Horswell, Stuart and Escudero, Mickael and Matthews, Nik and Rowan, Andrew and Chambers, Tim and Moore, David A and Turajlic, Samra and Xu, Hang and Lee, Siow-Ming and Forster, Martin D and Ahmad, Tanya and Hiley, Crispin T and Abbosh, Christopher and Falzon, Mary and Borg, Elaine and Marafioti, Teresa and Lawrence, David and Hayward, Martin and Kolvekar, Shyam and Panagiotopoulos, Nikolaos and Janes, Sam M and Thakrar, Ricky and Ahmed, Asia and Blackhall, Fiona and Summers, Yvonne and Shah, Rajesh and Joseph, Leena and Quinn, Anne M and Crosbie, Phil A and Naidu, Babu and Middleton, Gary and Langman, Gerald and Trotter, Simon and Nicolson, Marianne and Remmen, Hardy and Kerr, Keith and Chetty, Mahendran and Gomersall, Lesley and Fennell, Dean A and Nakas, Apostolos and Rathinam, Sridhar and Anand, Girija and Khan, Sajid and Russell, Peter and Ezhil, Veni and Ismail, Babikir and Irvin-Sellers, Melanie and Prakash, Vineet and Lester, Jason F and Kornaszewska, Malgorzata and Attanoos, Richard and Adams, Haydn and Davies, Helen and Dentro, Stefan and Taniere, Philippe and O’Sullivan, Brendan and Lowe, Helen L and Hartley, John A and Iles, Natasha and Bell, Harriet and Ngai, Yenting and Shaw, Jacqui A and Herrero, Javier and Szallasi, Zoltan and Schwarz, Roland F and Stewart, Aengus and Quezada, Sergio A and Le Quesne, John and Van Loo, Peter and Dive, Caroline and Hackshaw, Allan and Swanton, Charles and TRACERx Consortium
The New England journal of medicine, ISSN 1533-4406, 06/2017, Volume 376, Issue 22, pp. 2109 - 2121
Journal Article